Please find below a statement of the holding of the Novo Nordisk share as per the closure of the trading window as reported to Novo Nordisk.
Click the link 'Share portfolio (PDF)' at the top to see the share portfolio and the share option portfolio.
Background information and definitions re holding of shares:
Note that in the period 1 January - 25 February 2002 Tove Funder-Nielsen left the Board of Directors, Johnny Henriksen was elected to the Board of Directors and Lise Kingo, executive vice president, joined the Executive Management. Their shares have been included under 'Movements in the period 1 January - 13 November2002'.
Note that in the period 1 January - 25 February 2002 Tove Funder-Nielsen left the Board of Directors, Johnny Henriksen was elected to the Board of Directors and Lise Kingo, executive vice president, joined the Executive Management. Their shares have been included under 'Movements in the period 1 January - 13 November2002'.
What is the trading window?
Novo Nordisk's internal rules on trading in Novo Nordisk securities permit trading in such securities by insiders and connected persons in the 15-calendar-day period following each quarterly announcement.
Novo Nordisk's internal rules on trading in Novo Nordisk securities permit trading in such securities by insiders and connected persons in the 15-calendar-day period following each quarterly announcement.
Who are all insiders and connected persons?
Insiders at Novo Nordisk are defined as members of the Board of Directors, members of the Executive Management, senior vice presidents and all employees reporting directly to them, all employees in Legal Department, Corporate Finance, Investor Relations and Corporate Communications, elected auditors and their deputies as well as certain other employees who by the general counsel have been categorised as insiders. Further, insiders include the following from Novo Nordisk's parent organisation, Novo A/S, and the Novo Nordisk
Insiders at Novo Nordisk are defined as members of the Board of Directors, members of the Executive Management, senior vice presidents and all employees reporting directly to them, all employees in Legal Department, Corporate Finance, Investor Relations and Corporate Communications, elected auditors and their deputies as well as certain other employees who by the general counsel have been categorised as insiders. Further, insiders include the following from Novo Nordisk's parent organisation, Novo A/S, and the Novo Nordisk
Foundation: members of the Board of Directors, members of Management and other employees who have access to inside information re Novo Nordisk, as well as elected auditors. The insider register at Novo Nordisk comprises approximately 500 directors, executives and employees.
This group's reported trading in the Novo Nordisk share also includes trading undertaken by insiders' spouses/cohabitants or children under the age of 18 as well as any company, foundation and/or other businesses controlled by the insider, his/her spouse/cohabitant and/or children under the age of 18 (connected persons). This brings the group to a total of approximately 1,500-2,000 members.
What are ID code and shares?
The ID code DK001028081 is the code (ISIN) of the Novo Nordisk share on the Copenhagen Stock Exchange. Shares include shares listed on the Copenhagen Stock Exchange and London Stock Exchange as well as ADRs listed on New York Stock Exchange, except for ADRs held in 401(k) retirement plan by US-based employees.
The ID code DK001028081 is the code (ISIN) of the Novo Nordisk share on the Copenhagen Stock Exchange. Shares include shares listed on the Copenhagen Stock Exchange and London Stock Exchange as well as ADRs listed on New York Stock Exchange, except for ADRs held in 401(k) retirement plan by US-based employees.
What is market value of the total shareholding?
The market value is the total shareholding of the members of the Board of Directors, of the members of the Executive Management and of the insiders and connected persons as a group, respectively, multiplied by the closing share price on the Copenhagen Stock Exchange on 20 February 2003 of DKK 197.5.
The market value is the total shareholding of the members of the Board of Directors, of the members of the Executive Management and of the insiders and connected persons as a group, respectively, multiplied by the closing share price on the Copenhagen Stock Exchange on 20 February 2003 of DKK 197.5.
Background information and definitions re holding of options:
As far as options granted in 2000 are concerned please note that the options granted with an exercise period of 2004-07 relates to the combined 'share investment scheme' and 'option grant scheme' launched in connection with the demerger of Novozymes.
As far as options granted in 2000 are concerned please note that the options granted with an exercise period of 2004-07 relates to the combined 'share investment scheme' and 'option grant scheme' launched in connection with the demerger of Novozymes.
Also note that since 31 December 2001 Lise Kingo, executive vice president, has joined the Executive Management. Her share option portfolio has been included in the number of share options listed as 'Options outstanding on 13 November 2002'.
What is market value of options?
The calculation of market values of the options is based on the Black-Scholes option-pricing model. Closing price on the Copenhagen Stock Exchange on Thursday 20 February 2003 of DKK 197.5 is used.
The calculation of market values of the options is based on the Black-Scholes option-pricing model. Closing price on the Copenhagen Stock Exchange on Thursday 20 February 2003 of DKK 197.5 is used.
Novo Nordisk is a focused healthcare company and a world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs approximately 18,000 people in 68 countries and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For further company information visit www.novonordisk.com.
For further information please contact:
Media:
Outside North America:
Elin K Hansen
Tel (direct): (+45) 4442 3450
Outside North America:
Elin K Hansen
Tel (direct): (+45) 4442 3450
In North America:
Susan Jackson
Tel (direct): (+1) 609 919 7776
Susan Jackson
Tel (direct): (+1) 609 919 7776
Investors:
Outside North America:
Peter Haahr
Tel (direct): (+45) 4442 1207
Outside North America:
Peter Haahr
Tel (direct): (+45) 4442 1207
Palle Holm Olesen
Tel (direct): (+45) 4442 6175
Tel (direct): (+45) 4442 6175
Christian Kanstrup
Tel (direct): (+45) 4443 7801
Tel (direct): (+45) 4443 7801
In North America
Rasmus Jorgensen
Tel (direct): (+1) 212 582 3676
Rasmus Jorgensen
Tel (direct): (+1) 212 582 3676
Stock Exchange Announcement No 5 / 2003
